Cost of Health Screening per Patient in Low-Resource Settings

Finance leads and donor program officers reviewing screening budgets across Sub-Saharan Africa run into the same problem: the headline figures rarely survive contact with the field. A line item that reads "screening" might mean a single blood pressure check at a clinic door, or it might mean a multi-stop campaign that transports staff, equipment, and consumables across districts with no paved roads. Understanding the true cost of community health screening Africa programs requires separating the per-patient unit cost from the program overhead that quietly consumes most grant budgets. This analysis breaks down what the published evidence says about screening cost per patient, where the money actually goes, and how mHealth budgeting changes the math.

A 2025 scoping review of community health worker programs in low- and middle-income countries found costs per beneficiary ranging from $1.20 to $26,556, a spread that reflects how much delivery model and overhead drive total cost rather than the screening act itself. , Costs and cost-effectiveness of community health worker programs, PLOS Global Public Health, 2025

What drives the cost of community health screening Africa programs

The most common mistake in screening budgets is treating the cost per patient as a fixed clinical number. It is not. The clinical measurement, taking a blood pressure reading, checking a heart rate, assessing respiratory rate, is among the cheapest parts of the workflow. What inflates the figure is everything wrapped around it: transport to reach dispersed populations, per diems for staff, device procurement and calibration, consumables, supervision, and data capture.

Published cost-effectiveness work bears this out. A systematic review of hypertension management by non-physician health workers in LMICs, summarizing studies through May 2024, reported a cost per controlled patient as low as $INT 1.48 and a cost per mmHg of systolic reduction of roughly $INT 2.25. Yet annual per-person costs in the same body of literature ranged from $INT 0.22 to $INT 232.31. The clinical task is similar across these studies. The difference is delivery model, staffing intensity, and equipment.

For testing-based screening, the pattern repeats. A systematic review of HIV testing services in Sub-Saharan Africa found self-testing delivered a mean cost of $12.75 per person tested, while campaign-style testing reached $27.64 per person. Same outcome, more than double the cost, driven almost entirely by logistics and labor.

Comparing screening delivery models on cost per patient

The table below summarizes the broad cost ranges drawn from the reviewed literature. Figures are indicative unit costs per person screened or tested and should be treated as planning ranges, not fixed quotes, because local wages, distances, and disease focus shift them substantially.

Delivery model	Indicative cost per patient	Equipment burden	Main cost driver	Scalability
Facility-based clinical screening	$15 to $30+	High (calibrated devices)	Fixed infrastructure, staff time	Limited by clinic catchment
Campaign or outreach screening	$26 to $28 per person tested	Medium to high	Transport, per diems, logistics	Moderate, cost rises with reach
Community health worker, device-based	$1.20 to $26,556 per beneficiary	Medium	Supervision, device upkeep, training	Variable, depends on overhead
Self-testing models	~$12.75 per person tested	Low	Test kits, distribution	High for suitable conditions
Smartphone-based vitals screening	Low marginal cost per scan	Very low (no dedicated device)	Initial training, supervision	High, uses existing phones

Two observations matter for budget planning:

• The headline unit cost is dominated by overhead and logistics, not the measurement itself. Cutting transport and equipment costs has more use than optimizing the clinical step.
• Models that remove dedicated hardware shift cost from capital expenditure to marginal per-scan cost, which improves the economics of reaching the last patient in a dispersed population.

Why traditional cost models underestimate the true figure

Donor budgets frequently understate per-patient cost because they exclude indirect items. The Community Health Planning and Costing Tool, applied across six Sub-Saharan African countries and documented in Global Health: Science and Practice, was designed precisely because integrated community health packages carried hidden costs that single-intervention budgets missed. Supervision, supply chain, retraining after staff turnover, and device replacement are recurring expenses that a one-time procurement line never captures.

For equipment-dependent screening, depreciation and calibration are persistent drains. A blood pressure cuff or pulse oximeter has a finite service life, requires periodic recalibration, and fails in dusty, high-heat, off-grid conditions. Each replacement cycle resets the capital cost. When a program serves a population spread across hundreds of square kilometers, the device-to-patient ratio is poor, and idle equipment still depreciates.

Industry applications for budget and donor planning

mHealth budgeting and the shift to marginal cost

The strongest argument for mHealth budgeting is structural. When the screening tool is software running on a phone a health worker already owns, the dedicated-device line largely disappears. The cost model shifts from "how many devices must we buy and replace" to "what is the marginal cost of one additional scan." That marginal cost is close to zero for the measurement itself, leaving training, supervision, and data systems as the real budget lines. For finance leads, this converts a lumpy capital expense into a predictable operating expense that scales smoothly with coverage.

Donor cost-effectiveness and the ROI case

Donors increasingly evaluate programs on cost per disability-adjusted life-year (DALY) averted rather than cost per screen. The hypertension literature found most non-physician delivery models fell within accepted cost-effectiveness thresholds for LMICs. Earlier detection through cheaper, wider screening moves cases upstream, where management costs far less than late-stage treatment. The ROI argument is not that screening is free, it is that affordable health checks LMIC programs prevent the expensive downstream events. A screening model that doubles coverage at the same budget improves the cost-per-case-detected ratio even if the per-scan cost is similar.

National program integration

Health ministries planning at population scale care about total system cost. Integrating contactless vitals into existing touchpoints, immunization days, antenatal visits, community health worker rounds, spreads fixed costs across more contacts. This is the same logic that made self-testing cheaper than campaign testing: use the infrastructure that already exists rather than building parallel logistics.

Current research and evidence

The evidence base is consistent on a few points. First, community-delivered screening by non-physician workers is generally cost-effective in LMIC settings, as documented in the 2024 systematic review on hypertension management and the broader cost-effectiveness review from Johns Hopkins researchers. Second, the cost-effectiveness of population screening for cardiovascular disease and diabetes in LMICs, reviewed in Frontiers in Public Health, depends heavily on the prevalence of the target condition and the cost of the screening step, which is exactly where low-cost tools change the equation.

Third, the wide cost ranges reported, from $1.20 to over $26,000 per beneficiary in the 2025 PLOS Global Public Health review, are a warning against single-figure budgeting. The same review noted that programs targeting HIV, TB, and malaria were generally cost-effective compared with facility-based care, reinforcing that decentralization lowers cost when overhead is controlled.

What the literature still lacks is robust, head-to-head costing of smartphone-based vitals screening against device-based methods at scale. Most published figures predate widespread deployment of camera-based vital sign measurement, leaving a gap that field costing studies are only beginning to fill.

The future of screening cost per patient

The direction of travel is toward lower marginal cost and higher coverage. As measurement migrates from dedicated hardware to software on existing phones, the dominant cost line shifts permanently to people and data systems. That has two consequences for planners. Budgets will become more predictable, because operating costs scale linearly rather than in capital lumps. And the marginal economics of reaching the hardest-to-serve populations improve, because the last scan in a remote village no longer requires transporting fragile equipment.

The open question is total cost of ownership over a multi-year program horizon. Software needs updates, devices need management, and health workers need ongoing training and supervision regardless of the tool. The programs that win on cost will be the ones that model the full life cycle, not just the procurement quote, and that build screening into existing service contacts rather than running it as a standalone campaign.

Frequently asked questions

What is a realistic per-patient cost for community screening in Sub-Saharan Africa? Published ranges are wide. Testing-based screening has shown roughly $12 to $28 per person depending on whether it is self-administered or campaign-delivered, while community health worker programs span $1.20 to over $26,000 per beneficiary depending on overhead and disease focus. Use ranges for planning, not single figures.

Why do screening budgets so often exceed their estimates? Most overruns come from indirect costs that initial budgets omit: transport, supervision, device calibration and replacement, staff turnover, and retraining. Costing tools developed for Sub-Saharan Africa exist specifically because integrated community packages carry these hidden recurring expenses.

How does smartphone-based screening change the cost model? It shifts cost from capital expenditure on dedicated devices to a near-zero marginal cost per scan, leaving training, supervision, and data systems as the main budget lines. This makes costs more predictable and improves the economics of reaching dispersed populations.

Is cheaper screening actually more cost-effective? Not automatically. Cost-effectiveness depends on the prevalence of the target condition and what happens after detection. Cheaper screening improves cost per case detected only when it is paired with a referral and treatment pathway that acts on the results.

Circadify is working on this exact problem, deploying smartphone-based vital signs screening in Uganda that removes the dedicated-device line from screening budgets and converts capital cost into predictable marginal cost. Donors and finance leads who want a costing model built around their own coverage targets and population spread can review the field data and partnership details in the global health section at circadify.com/blog.